Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00785421Phase 2Completed

Chemotherapy With or Without Enoxaparin in Pancreatic Cancer

Role: lead

NCT01945879Phase 1Completed

Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer

Role: lead

NCT00786058Unknown

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

Role: lead

NCT00919282Phase 2Completed

Gemcitabine (GFF) in Patients With Pancreatic Cancer

Role: lead

NCT00919659Phase 2Completed

Parenteral Nutrition Support for Patients With Pancreatic Cancer

Role: lead

NCT00759226Phase 2Completed

Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer

Role: lead

All 6 trials loaded